ReproCELL Inc (4978):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ReproCELL Inc (4978) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8092
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ReproCELL Inc (ReproCELL) is a biotechnology company that develops and commercializes stem cell technologies. The company offers products in divisions such as research reagents, cultivation materials, and cell and biorepository. Its research reagent products include hES iPSC culture reagents, human HSC culture reagent, reprogramming regent for iPSC, small molecule, pluripotency marker, and culture reagents for cancer research. ReproCELL’s cell and biorepository products comprise human iPS cells derived cardiomyocytes, hiPSC-neurons, hiPSC-hepatocytes, hiPSC-disease model cells and biorepository. The company markets its products across Japan. ReproCELL is headquartered in Yokohama, Japan.

ReproCELL Inc (4978) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReproCELL Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReproCELL Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 13
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 14
Venture Financing 15
Kringle Pharma Raises USD5.4 Million in Venture Financing 15
Reinnervate Secures USD0.16 Million in Venture Funding 17
Reinnervate Secures USD1.72 Million in Venture Funding 18
Stemgent Raises US$11.3 Million In Venture Financing 19
Stemgent Raises US$6.3 Million In Series C Financing 20
Partnerships 21
Q Therapeutics Forms Joint Venture with REPROCELL 21
Q Therapeutics Announces Research Agreement with ReproCELL 22
ReproCELL and Fox Chase Cancer Center Enter into Partnership 23
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Three-Dimensional Bioprinting Product Lines 24
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Cell Culture Products 25
ReproCELL Enters Into Distribution Agreement With Laboratorios Conda 26
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 27
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 28
Reinnervate Enters Into Co-Development Agreement With Kirkstall 29
Licensing Agreements 30
ReproCELL Receives Rights of Stemchymal Cell Therapy Technology from Steminent Biotherapeutics 30
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 31
Equity Offering 32
ReproCELL Completes IPO For US$20.8 Million 32
Asset Transactions 34
ReproCELL to Sell ReproHP Medium 34
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 35
Acquisition 36
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
ReproCELL Plans to Acquire 7.44% Stake in ReproCELL USA 37
ReproCELL to Acquire Biopta for USD8.2 Million 38
ReproCELL Acquires BioServe Biotechnologies 40
ReproCELL Acquires Reinnervate 41
ReproCELL Inc – Key Competitors 42
ReproCELL Inc – Key Employees 43
ReproCELL Inc – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Joint Venture 45
Recent Developments 46
Other Significant Developments 46
Jun 21, 2018: Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
ReproCELL Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReproCELL Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReproCELL Inc, Deals By Therapy Area, 2012 to YTD 2018 9
ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 13
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 14
Kringle Pharma Raises USD5.4 Million in Venture Financing 15
Reinnervate Secures USD0.16 Million in Venture Funding 17
Reinnervate Secures USD1.72 Million in Venture Funding 18
Stemgent Raises US$11.3 Million In Venture Financing 19
Stemgent Raises US$6.3 Million In Series C Financing 20
Q Therapeutics Forms Joint Venture with REPROCELL 21
Q Therapeutics Announces Research Agreement with ReproCELL 22
ReproCELL and Fox Chase Cancer Center Enter into Partnership 23
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Three-Dimensional Bioprinting Product Lines 24
n3D Biosciences Enters into Distribution Agreement with ReproCELL for Cell Culture Products 25
ReproCELL Enters Into Distribution Agreement With Laboratorios Conda 26
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 27
Reinnervate Enters Into Co-Development Agreement With Roslin Cellab 28
Reinnervate Enters Into Co-Development Agreement With Kirkstall 29
ReproCELL Receives Rights of Stemchymal Cell Therapy Technology from Steminent Biotherapeutics 30
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 31
ReproCELL Completes IPO For US$20.8 Million 32
ReproCELL to Sell ReproHP Medium 34
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 35
ReproCELL Acquires BioServe Biotech from Cancer Genetics for USD1.9 Million 36
ReproCELL Plans to Acquire 7.44% Stake in ReproCELL USA 37
ReproCELL to Acquire Biopta for USD8.2 Million 38
ReproCELL Acquires BioServe Biotechnologies 40
ReproCELL Acquires Reinnervate 41
ReproCELL Inc, Key Competitors 42
ReproCELL Inc, Key Employees 43
ReproCELL Inc, Other Locations 44
ReproCELL Inc, Subsidiaries 44
ReproCELL Inc, Joint Venture 45

List of Figures
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
ReproCELL Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
ReproCELL Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[ReproCELL Inc (4978):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Universal Travel Group:企業の戦略・SWOT・財務分析
    Universal Travel Group - Strategy, SWOT and Corporate Finance Report Summary Universal Travel Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Ampio Pharmaceuticals Inc (AMPE):製薬・医療:M&Aディール及び事業提携情報
    Summary Ampio Pharmaceuticals Inc (Ampio), formerly Chay Enterprises Inc is a biopharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by …
  • Verizon Communications Inc.:企業の戦略・SWOT・財務情報
    Verizon Communications Inc. - Strategy, SWOT and Corporate Finance Report Summary Verizon Communications Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Mesa Laboratories Inc (MLAB):企業の財務・戦略的SWOT分析
    Summary Mesa Laboratories Inc (Mesa) is a medical device company. It manufactures and markets validation and monitoring instruments. The company’s products include mesa biological indicators, DryCal gas flow calibrators, BGI ambient particulate sampling, DialyGuard dialysate meters, SureTorque cap t …
  • Minnesota Valley Electric Cooperative:企業の戦略的SWOT分析
    Minnesota Valley Electric Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • China Non-ferrous Metal Industry’s Foreign Engineering and Construction Co Ltd:企業の戦略・SWOT・財務分析
    China Non-ferrous Metal Industry's Foreign Engineering and Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Non-ferrous Metal Industry's Foreign Engineering and Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data …
  • Spectris plc:企業の戦略・SWOT・財務分析
    Spectris plc - Strategy, SWOT and Corporate Finance Report Summary Spectris plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Univar Solutions Inc (UNVR):企業の財務・戦略的SWOT分析
    Univar Solutions Inc (UNVR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Pacific Mutual Holding Company:企業の戦略的SWOT分析
    Pacific Mutual Holding Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • Viking Therapeutics Inc (VKTX):企業の財務・戦略的SWOT分析
    Summary Viking Therapeutics Inc (Viking Therapeutics) is a clinical-stage biopharmaceutical company that develops novel therapies for patients suffering from metabolic and endocrine disorders. The company’s lead clinical program product candidate include VK5211, an orally available, non-steroidal se …
  • Shanghai Jin Jiang International Hotels (Group) Co Ltd:企業の戦略・SWOT・財務情報
    Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Shanghai Jin Jiang International Hotels (Group) Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • The J.M. Smucker Co:企業の戦略・SWOT・財務情報
    The J.M. Smucker Co - Strategy, SWOT and Corporate Finance Report Summary The J.M. Smucker Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • United Food Holdings Limited:企業の戦略・SWOT・財務分析
    United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary United Food Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Demant AS (DEMANT):企業の財務・戦略的SWOT分析
    Demant AS (DEMANT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Landis+Gyr AG (LAND):電力:M&Aディール及び事業提携情報
    Summary Landis+Gyr AG (Landis+Gyr) is an integrated energy management company that provide end-to-end advanced metering solutions. It delivers comprehensive services including cloud services, managed services, smart grid services, software services, solutions consulting and support services. The com …
  • CVS Health Corp (CVS):製薬・医療:M&Aディール及び事業提携情報
    Summary CVS Health Corporation (CVS) is an integrated prescription and related health services provider. The company offers a range of solutions such as prescription medications; health care products; popular beauty, health and personal care brands; retail-based health clinical services; and pharmac …
  • Kellogg Co:戦略・SWOT・企業財務分析
    Kellogg Co - Strategy, SWOT and Corporate Finance Report Summary Kellogg Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Tenet Healthcare Corp (THC):企業の財務・戦略的SWOT分析
    Tenet Healthcare Corp (THC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Verona Pharma Plc (VRP):製薬・医療:M&Aディール及び事業提携情報
    Summary Verona Pharma Plc (Verona Pharma) is a clinical-stage biotechnology company, which focuses on the research, discovery and development of first-in-class therapeutic drugs for the treatment of chronic respiratory and inflammatory diseases. The company's lead candidate, RPL554 is a bronchodilat …
  • Taiga Building Products Ltd (TBL):企業の戦略的SWOT分析
    Taiga Building Products Ltd (TBL) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆